Merck Loses Almost $52B in 6 Months: How to Play MRK Stock

The stock of Merck (MRK) has declined 19.2% in the past six months, losing almost $52 billion of its market valueThe numerous challenges plaguing the company resulted in the dilution of the stock’s market value. Rising competitive pressure on the diabetes franchise and persistent challenges for its human papillomavirus vaccine, Gardasil in China remain overhangs. There are concerns about Merck’s ability to successfully navigate the loss of exclusivity period for its blockbuster drug, Keytruda, and potential ...